

Table S1. Description of the orally administered antineoplastics included in the study.

ORALLY ADMINISTERED ANTINEOPLASTICS	N	%
IMMUNOMODULATORS	44	16.4
<i>LENALIDOMIDE</i>	41	15.3
<i>POMALIDOMIDE</i>	3	1.1
CYTOTOXIC CHEMOTHERAPY	34	12.7
<i>CAPECITABINE</i>	25	9.3
<i>TEMOZOLOMIDE</i>	3	1.1
<i>TRIFLURIDINE + TIPIRACIL</i>	4	1.5
<i>LOMUSTINE</i>	1	0.4
<i>VINORELBINE</i>	1	0.4
DIRECTED THERAPIES	186	72.4
<i>IBRUTINIB</i>	29	10.8
<i>ABIRATERONE</i>	19	7.1
<i>RIBOCICLIB</i>	16	6
<i>PALBOCICLIB</i>	10	3.7
<i>ENZALUTAMIDE</i>	9	3.4
<i>RUXOLITINIB</i>	9	3.4
<i>IMATINIB</i>	8	3
<i>NILOTINIB</i>	8	3
<i>OLAPARIB</i>	8	3
<i>OSIMERTINIB</i>	8	3
<i>DASATINIB</i>	6	2.2
<i>NINTEDANIB</i>	6	2.2
<i>SUNITINIB</i>	6	2.2
<i>ABEMACICLIB</i>	5	1.9
<i>ALECTINIB</i>	4	1.5
<i>DABRAFENIB + TRAMETINIB</i>	4	1.5
<i>CABOZANTINIB</i>	3	1.1
<i>EVEROLIMUS</i>	3	1.1
<i>NIRAPARIB</i>	3	1.1
<i>PAZOPANIB</i>	3	1.1
<i>SORAFENIB</i>	3	1.1
<i>LAPATINIB</i>	2	0.8
<i>REGORAFENIB</i>	2	0.8
<i>VENETOCLAX</i>	2	0.8
<i>VISMODEGIB</i>	2	0.8
<i>AFATINIB</i>	1	0.4
<i>ALPESINIB</i>	1	0.4
<i>AXITINIB</i>	1	0.4
<i>ENCORAFENIB</i>	1	0.4
<i>LENVATINIB</i>	1	0.4
<i>PONATINIB</i>	1	0.4

<i>TIVOZANIB</i>	<i>1</i>	<i>0.4</i>
<i>VANDETANIB</i>	<i>1</i>	<i>0.4</i>
OTHER	4	1.5
<i>ANAGRELIDE</i>	<i>4</i>	<i>1.5</i>
TOTAL	268	100